Nuvectis Pharma, Inc. (NVCT) Stock Price & Analysis
Nuvectis Pharma, Inc. (NVCT) fell 2.04% to USD 23.99 as of September 9, 2026 at 13:26 UTC, according to Nexqual real-time market data.
NVCT last closed at USD 24.49; the session ranged USD 22.73–24.69 on volume of 136,161 shares. Market capitalization is $783.13M, with a 52-week range of USD 5.55–29.28 (NCM). Source: Nexqual, September 9, 2026 at 13:26 UTC.
Key Statistics (as of September 9, 2026 at 13:26 UTC)
| Price | USD 23.99 |
|---|---|
| Change | ▼ 2.04% (down) |
| Previous Close | USD 24.49 |
| Open | USD 23.59 |
| Day Range | USD 22.73 – 24.69 |
| 52-Week Range | USD 5.55 – 29.28 |
| Volume | 136,161 shares |
| Market Cap | $783.13M |
| Exchange | NCM |
Technical Analysis (NVCT)
Nexqual's technical model rates NVCT "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of September 9, 2026 at 13:26 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 58.85 (neutral) |
| vs SMA50 | Above (USD 20.93) |
| MACD | 1.17 (positive) |
Analyst Ratings (NVCT)
Wall Street analysts rate NVCT "Strong Buy" based on 5 analysts, with a mean price target of USD 35.4 (range USD 30–40), per Nexqual as of September 9, 2026 at 13:26 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 35.4 |
| High Target | USD 40 |
| Low Target | USD 30 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (NVCT)
| Next Earnings Date | 2026-11-03 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.3 vs est -0.26 ▼ miss |
| 2026-03-31 | USD -0.26 vs est -0.31 ▲ beat |
| 2025-12-31 | USD -0.31 vs est -0.31 ▼ miss |
| 2025-09-30 | USD -0.44 vs est -0.25 ▼ miss |
Source: Nexqual, September 9, 2026 at 13:26 UTC.
Financials & Fundamentals (NVCT)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -214.58% |
| Current Ratio | 1.68 |
| Total Cash | $22.16M |
| Total Debt | $0 |
| Free Cash Flow | $-8.89M |
Source: Nexqual, September 9, 2026 at 13:26 UTC.
Financial Health Score (NVCT)
Nexqual rates Nuvectis Pharma, Inc.'s overall financial health "Weak" across five dimensions, as of September 9, 2026 at 13:26 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $22M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$20M |
| Efficiency | Critical — ROE -215%, ROA -73.1% |
Ownership (NVCT)
| Insider Ownership | +34.43% |
|---|---|
| Institutional Ownership | +33.56% |
| Shares Outstanding | 32.64M |
| Float | 21.20M |
| Short % of Float | +8.47% |
Source: Nexqual, September 9, 2026 at 13:26 UTC.
Leadership (NVCT)
Nuvectis Pharma, Inc. is led by Ron Bentsur (age 59), Co-Founder, Chairman, CEO & President, per Nexqual as of September 9, 2026 at 13:26 UTC.
| Co-Founder, Chairman, CEO & President | Ron Bentsur (age 59) |
|---|---|
| Co-Founder, Executive VP, Chief Scientific & Business Officer | Enrique Poradosu (age 58) |
| Vice President of Finance | Michael Carson (age 49) |
Major Backers & Investors (NVCT)
Notable institutional backers of Nuvectis Pharma, Inc. include Tang Capital Management, LLC, Soleus Capital Management, L.P., Perceptive Advisors Llc, according to Nexqual as of September 9, 2026 at 13:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Tang Capital Management, LLC | 4.75% |
| Soleus Capital Management, L.P. | 3.06% |
| Perceptive Advisors Llc | 3.06% |
| Iridian Asset Management LLC | 2.38% |
| Baldwin Wealth Partners LLC/MA | 1.17% |
| Sphera Funds Management Ltd. | 1.17% |
| Fidelity | 1.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.04% |
| Vanguard Group | 5% |
| Geode Capital | 1.32% |
Source: Nexqual, September 9, 2026 at 13:26 UTC.
From Nuvectis Pharma, Inc.'s Latest SEC 10-K Filing (filed 2026-02-11)
Key Strengths & Strategy (as disclosed to the SEC)
- Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology.
- The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IMMX | Immix Biopharma, Inc. | USD 13.25 | ▼ 4.19% |
| NRSN | NeuroSense Therapeutics Ltd. | USD 0.42 | ▲ 4% |
| ANGH | Anghami Inc. | USD 3.46 | ▼ 6.49% |
| TRDA | Entrada Therapeutics, Inc. | USD 7.52 | ▲ 4.88% |
| FHTX | Foghorn Therapeutics Inc. | USD 4.83 | ▼ 0.82% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 13:26 UTC. This page is informational and not investment advice.